tailieunhanh - Báo cáo hóa học: "Hybrid approach of ventricular assist device and autologous bone marrow stem cells implantation in end-stage ischemic heart failure enhances myocardial reperfusion"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành hóa học dành cho các bạn yêu hóa học tham khảo đề tài: Hybrid approach of ventricular assist device and autologous bone marrow stem cells implantation in end-stage ischemic heart failure enhances myocardial reperfusion. | Anastasiadis et al. Journal of Translational Medicine 2011 9 12 http content 9 1 12 TRANSLATIONAL MEDICINE COMMENTARY Open Access Hybrid approach of ventricular assist device and autologous bone marrow stem cells implantation in end-stage ischemic heart failure enhances myocardial reperfusion 1 1 1 2 A P s 3 Kyriakos Anastasiadis Polychronis Antonitsis Helena Argiriadou Georgios Koliakos Argyrios Doumas Andre Khayat4 Christos Papakonstantinou1 Stephen Westaby5 Abstract We challenge the hypothesis of enhanced myocardial reperfusion after implanting a left ventricular assist device together with bone marrow mononuclear stem cells in patients with end-stage ischemic cardiomyopathy. Irreversible myocardial loss observed in ischemic cardiomyopathy leads to progressive cardiac remodelling and dysfunction through a complex neurohormonal cascade. New generation assist devices promote myocardial recovery only in patients with dilated or peripartum cardiomyopathy. In the setting of diffuse myocardial ischemia not amenable to revascularization native myocardial recovery has not been observed after implantation of an assist device as destination therapy. The hybrid approach of implanting autologous bone marrow stem cells during assist device implantation may eventually improve native cardiac function which may be associated with a better prognosis eventually ameliorating the need for subsequent heart transplantation. The aforementioned hypothesis has to be tested with well-designed prospective multicentre studies. Introduction Left ventricular assist devices LVADs are increasingly used as bridge to transplantation in patients with endstage heart failure HF or more recently as destination therapy in non-transplant candidates. Encouraging results with LVADs as a bridge to recovery have been reported from the Berlin group in patients with idiopathic dilated cardiomyopathy IDCM 1 and by Simon and colleagues in patients with peripartum cardiomyopathy